Roundtable Discussion: Resistance Risks? Comparing Cell Engagers to Alternate Cancer Treatments Such as ADCs & Cell Therapies to Evaluate Potential Risks
Time: 12:00 pm
day: Conference Day 1
Details:
- Question the learnings from alternate therapeutic strategies such as how CAR T developers manage CRS
- Balance how cell engagers can fit into the standard of care or following patient treatment with these therapies
- Discuss future directions and the looming risk of resistance. Can we prevent it ever developing?
